Orphazyme A/S
Arimoclomol formulation

Last updated:

Abstract:

The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.

Status:
Grant
Type:

Utility

Filling date:

23 Mar 2020

Issue date:

25 Jan 2022